Palexia Depot for Severe chronic pain requiring around-the-clock analgesia

Quick answer: Palexia Depot is used for Severe chronic pain requiring around-the-clock analgesia as part of a centrally acting opioid analgesic (mor agonist + nri), extended-release treatment regimen. Extended-release tapentadol: dual mu-opioid receptor agonism and norepinephrine reuptake inhibition with prolonged release profile The specific dosing for Severe chronic pain requiring around-the-clock analgesia is determined by your prescriber based on individual factors.

Why is Palexia Depot used for Severe chronic pain requiring around-the-clock analgesia?

Palexia Depot belongs to the Centrally acting opioid analgesic (MOR agonist + NRI), extended-release class. Extended-release tapentadol: dual mu-opioid receptor agonism and norepinephrine reuptake inhibition with prolonged release profile This action makes it useful for treating or managing Severe chronic pain requiring around-the-clock analgesia in patients for whom this approach is clinically appropriate.

It is one of several treatment options. Whether Palexia Depot is the right choice for a specific patient depends on the type and severity of Severe chronic pain requiring around-the-clock analgesia, response to previous treatments, individual risk factors, and clinical guidelines.

Typical dosing for Severe chronic pain requiring around-the-clock analgesia

Common adult dosing range: 50-250 mg twice daily. The actual dose for Severe chronic pain requiring around-the-clock analgesia depends on:

For complete dosing details, see the Palexia Depot medicine page.

What to expect

Palexia Depot treatment for Severe chronic pain requiring around-the-clock analgesia typically involves:

Alternatives to consider

If Palexia Depot is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Centrally acting opioid analgesic (MOR agonist + NRI), extended-release for related options.

When to talk to your doctor

Discuss with your prescriber if you experience:

Related information

Palexia Depot full prescribing information ยท All Centrally acting opioid analgesic (MOR agonist + NRI), extended-release alternatives

Medical disclaimer: This tool provides educational information for general reference. It is not a substitute for professional medical advice, diagnosis, or treatment. Always discuss your individual situation with a qualified healthcare provider.

Frequently asked questions

How effective is Palexia Depot for Severe chronic pain requiring around-the-clock analgesia?

Effectiveness varies by individual response, dose, and severity. Palexia Depot is one of several treatment options for Severe chronic pain requiring around-the-clock analgesia, supported by clinical evidence within the centrally acting opioid analgesic (mor agonist + nri), extended-release class. Discuss expected response with your prescriber.

How long do I need to take Palexia Depot for Severe chronic pain requiring around-the-clock analgesia?

Treatment duration depends on the nature of Severe chronic pain requiring around-the-clock analgesia โ€” some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.

What are the main side effects of Palexia Depot when used for Severe chronic pain requiring around-the-clock analgesia?

Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.

Are there alternatives to Palexia Depot for Severe chronic pain requiring around-the-clock analgesia?

Yes. Multiple medicines and non-drug options exist for Severe chronic pain requiring around-the-clock analgesia. Alternatives within the centrally acting opioid analgesic (mor agonist + nri), extended-release class share mechanisms; other classes may offer different approaches. Discuss with your clinician.

Last reviewed: by iMedic Medical Editorial Team. Our editorial process.